摘要:
The present invention provides a mycotoxin adsorbent based on a highly specific betaine derivative for trichothecenes A and B, and especially for vomitoxin (or deoxynivalenol) and T-2 toxin; as well as a process for preparing said mycotoxin adsorbent. The mycotoxin adsorbent of the invention is obtained by modifying the surface of an aluminosilicate by means of an organic amphoteric compound with a carboxyl group that provides it with high polarity properties. The mycotoxin adsorbent is useful for preparing balanced feed from animals that avoid the toxic effects of mycotoxins.
摘要:
The invention provides a compound of formula (I): [insert formula (I)] wherein X, Y, and R1-R4 have any of the values defined in the specification, and salts thereof, as well as compositions comprising the compounds or salts. The compounds are useful for treating diseases associated with impaired mitochondrial function in an animal.
摘要:
The absorption of CO2 from a gas mixture by contacting the gas mixture with an absorption medium that comprises water and 5 to 50 wt % of amino acid salts of formula R1R2CHNHCH2COOK, in which R1 and R2 are n-alkyl radicals and the radicals R1 and R2 together have 2 to 4 carbon atoms, affords a high CO2 absorption capacity per unit weight in the cyclical operation of absorption and desorption.
摘要:
The invention provides a compound of formula (I): [insert formula (I)] wherein X, Y, and R1-R4 have any of the values defined in the specification, and salts thereof, as well as compositions comprising the compounds or salts. The compounds are useful for treating diseases associated with impaired mitochondrial function in an animal.
摘要:
The invention concerns compounds of formula (I) wherein in particular G represents the —N(CH3)2—, —N(C2H5)2-group or N-pyrrolidine: n is an integer equal to 1 or 2: R1, R2 and R3, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R1, R2, and R3 is different from H: and Y1 and Y2 represent each a —COOCH3 group or a COOC2H5 group.
摘要翻译:本发明涉及式(I)的化合物,其中特别是G代表-N(CH 3)2 - , - N(C 1 -C 6) H 5 - ) - 亚基或N-吡咯烷:n是等于1或2的整数:R 1,R 2 R 3和R 3'彼此独立地表示氢原子或甲基,连续的不饱和单元能够进一步相同或不同,条件是至少一个取代基R R 1,R 2,R 3和R 3不同于H 1和Y 1和Y 2 每一个代表一个-COOCH 3个3个基团或一个COOC 2 H 5 H 5基团。
摘要:
Carrier compounds, compositions, and dosage unit forms therefor which are useful in the delivery of active agents are provided. The present invention provides a compound having the formula: ##STR1## or a salt thereof, wherein the compound may be used in a composition or dosage unit form for delivery of at least one active agent, including a peptide, mucopolysaccharide, carbohydrate, or a lipid. Methods of administration and preparation of the compounds and compositions of the invention are provided as well, including oral administration. Further, the compositions of the invention may be prepared by mixing at least one active agent, at least one carrier compound, and, optionally, a dosing vehicle.
摘要:
Carrier compounds, compositions, and dosage unit forms therefor which are useful in the delivery of active agents are provided. The present invention provides a compound having the formula: ##STR1## or a salt thereof, wherein the compound may be used in a composition or dosage unit form for delivery of at least one active agent, including a peptide, mucopoly-saccharide, carbohydrate, of a lipid. Methods of administration and preparation of the compounds and compositions of the invention are provided as well, including oral administration. Further, the compositions of the invention may be prepared by mixing at least one active agent, at least one carrier compound, and, optionally, a dosing vehicle.
摘要:
According to the invention, an improved class of amphoteric surfactant having improved surfactant properties characterized as mild and environmentally safe has been provided comprising compounds of the formula: ##STR1## The amphoteric surfactant of the subject invention have at least two hydrophobic moieties and at least two hydrophilic groups per molecule and are useful as emulsifiers, detergents, dispersants and solubilizing agents.
摘要:
Compounds of Formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein Q is optionally substituted phenyl or naphthyl;X and Y are each H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or X and Y are together .dbd.O;Z is O or S;R.sup.1 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted phenyl (C.sub.1-4 alkyl), C.sub.2-6 alkenyl, COC.sub.1-6 alkylhalo, COR.sup.a, COOR.sup.a, CONHR.sup.a, COC.sub.1-6 alkylNR.sup.a R.sup.b or CONR.sup.a C.sub.1-6 alkylCONR.sup.a R.sup.b ;R.sup.2 is substituted C.sub.1-6 alkyl, optionally substituted phenyl(C.sub.1-4 alkyl), C.sub.2-6 alkenyl, C.sub.1-6 alkylhalo, COR.sup.a, COOR.sup.a, CONHR.sup.a, COC.sub.1-6 alkylNR.sup.a R.sup.b or CONR.sup.a C.sub.1-6 alkylCONR.sup.a R.sup.b ;or R.sup.1 and R.sup.2 together form a chain (CH.sub.2).sub.p optionally substituted by oxo;R.sup.3 is H [or C.sub.1-6 alkyl];R.sup.4 is H, C.sub.1-6 alkyl or phenyl; andR.sup.5 is optionally substituted (CH.sub.2).sub.q phenyl; are tachykinin antagonists useful for treating pain.
摘要翻译:PCT No.PCT / GB92 / 01241 Sec。 371日期:1993年12月17日 102(e)日期1993年12月17日PCT提交1992年7月8日PCT公布。 出版物WO93 / 01165 日期1993年1月21日式(I)化合物及其药学上可接受的盐:其中Q是任选取代的苯基或萘基; X和Y各自为H,C 1-6烷基,C 2-6烯基或X和Y一起= O; Z是O或S; R 1是H,任选取代的C 1-6烷基,任选取代的苯基(C 1-4烷基),C 2-6烯基,COC 1-6烷基卤素,CORA,COORa,CONHRa,COC 1-6烷基NR a R b或CONR a C 1-6烷基CONR a R b; R 2是取代的C 1-6烷基,任选取代的苯基(C 1-4烷基),C 2-6烯基,C 1-6烷基卤代,CORA,COORa,CONHRa,COC 1-6烷基NR a R b或CONR a C 1-6烷基CONR a R b; 或R 1和R 2一起形成任选被氧代取代的链(CH 2)p; R3是H [或C1-6烷基]; R4是H,C1-6烷基或苯基; 并且R 5是任选取代的(CH 2)q苯基; 是用于治疗疼痛的速激肽拮抗剂。
摘要:
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.